糖尿病视网膜病变的开发和新型疗法。

IF 2.4 Q3 ENDOCRINOLOGY & METABOLISM
Pravinkumar Ingle, Nurin Alesya Hamden, Wai Kei Soh, Rosalina Wibawa Hui Cen Loh, Ketan Hatware
{"title":"糖尿病视网膜病变的开发和新型疗法。","authors":"Pravinkumar Ingle, Nurin Alesya Hamden, Wai Kei Soh, Rosalina Wibawa Hui Cen Loh, Ketan Hatware","doi":"10.2174/0115733998324556240910061514","DOIUrl":null,"url":null,"abstract":"<p><p>Diabetic retinopathy (DR) is a complication of diabetes mellitus which causes retinal damage which when left untreated will cause visual problems. As the prevalence of DR increases over the years, there is a need to optimise the currently available treatments as well as developing novel drugs to improve the therapy provided for the patients in the clinical practice. Several pharmacological therapies like, anti-vascular endothelial growth factor and anti-inflammatory therapies which include intravitreal, and implant of corticosteroids are significant in the management to decrease the risk of DR-related vision impairment. Clinical trials for novel drug therapies are still ongoing till this day to enhance the efficacy of DR treatment. Even though there are also modern treatments such as laser therapy for the patients, prevention should be done to lower the number of individuals affected by DR. Due to the complexity of DR, there are numerous obstacles to develop new medications for DR which include the increasing healthcare cost of DR treatment. New insights such as utilisation of artificial intelligence will be implemented into the management of DR as it has proved its potential in aiding the screening process. In parallel with the increase in DR prevalence and the number of treatments developed, extensive understanding of the mechanism of action of DR should be further improved to prevent more complications in the future. This review summarises the epidemiological trend, prevention strategies, challenges in treatment, current novel therapeutics (including drugs under clinical trials), future therapeutic trends and possibilities for implementing AI in the early diagnosis and management of DR.</p>","PeriodicalId":10825,"journal":{"name":"Current diabetes reviews","volume":" ","pages":""},"PeriodicalIF":2.4000,"publicationDate":"2024-10-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Development and Novel Therapeutics in Diabetic Retinopathy.\",\"authors\":\"Pravinkumar Ingle, Nurin Alesya Hamden, Wai Kei Soh, Rosalina Wibawa Hui Cen Loh, Ketan Hatware\",\"doi\":\"10.2174/0115733998324556240910061514\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><p>Diabetic retinopathy (DR) is a complication of diabetes mellitus which causes retinal damage which when left untreated will cause visual problems. As the prevalence of DR increases over the years, there is a need to optimise the currently available treatments as well as developing novel drugs to improve the therapy provided for the patients in the clinical practice. Several pharmacological therapies like, anti-vascular endothelial growth factor and anti-inflammatory therapies which include intravitreal, and implant of corticosteroids are significant in the management to decrease the risk of DR-related vision impairment. Clinical trials for novel drug therapies are still ongoing till this day to enhance the efficacy of DR treatment. Even though there are also modern treatments such as laser therapy for the patients, prevention should be done to lower the number of individuals affected by DR. Due to the complexity of DR, there are numerous obstacles to develop new medications for DR which include the increasing healthcare cost of DR treatment. New insights such as utilisation of artificial intelligence will be implemented into the management of DR as it has proved its potential in aiding the screening process. In parallel with the increase in DR prevalence and the number of treatments developed, extensive understanding of the mechanism of action of DR should be further improved to prevent more complications in the future. This review summarises the epidemiological trend, prevention strategies, challenges in treatment, current novel therapeutics (including drugs under clinical trials), future therapeutic trends and possibilities for implementing AI in the early diagnosis and management of DR.</p>\",\"PeriodicalId\":10825,\"journal\":{\"name\":\"Current diabetes reviews\",\"volume\":\" \",\"pages\":\"\"},\"PeriodicalIF\":2.4000,\"publicationDate\":\"2024-10-02\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Current diabetes reviews\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.2174/0115733998324556240910061514\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q3\",\"JCRName\":\"ENDOCRINOLOGY & METABOLISM\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Current diabetes reviews","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.2174/0115733998324556240910061514","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"ENDOCRINOLOGY & METABOLISM","Score":null,"Total":0}
引用次数: 0

摘要

糖尿病视网膜病变(DR)是糖尿病的一种并发症,会造成视网膜损伤,如不及时治疗,将导致视力问题。随着糖尿病视网膜病变发病率的逐年上升,有必要优化现有的治疗方法并开发新型药物,以改善临床实践中为患者提供的治疗。一些药物疗法,如抗血管内皮生长因子和抗炎疗法,包括玻璃体内注射和植入皮质类固醇,对于降低 DR 相关视力损伤的风险具有重要意义。时至今日,新型药物疗法的临床试验仍在进行中,以提高 DR 的治疗效果。尽管也有激光治疗等现代治疗方法,但仍应做好预防工作,以减少 DR 患者的数量。由于 DR 的复杂性,开发治疗 DR 的新药物面临诸多障碍,其中包括 DR 治疗的医疗成本不断增加。人工智能在协助筛查过程中的潜力已得到证实,因此将在 DR 的管理中采用人工智能等新见解。随着 DR 发病率的增加和治疗方法的增多,应进一步广泛了解 DR 的作用机制,以防止未来出现更多并发症。本综述总结了 DR 的流行趋势、预防策略、治疗方面的挑战、当前的新型疗法(包括正在进行临床试验的药物)、未来的治疗趋势以及在早期诊断和管理中实施人工智能的可能性。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
Development and Novel Therapeutics in Diabetic Retinopathy.

Diabetic retinopathy (DR) is a complication of diabetes mellitus which causes retinal damage which when left untreated will cause visual problems. As the prevalence of DR increases over the years, there is a need to optimise the currently available treatments as well as developing novel drugs to improve the therapy provided for the patients in the clinical practice. Several pharmacological therapies like, anti-vascular endothelial growth factor and anti-inflammatory therapies which include intravitreal, and implant of corticosteroids are significant in the management to decrease the risk of DR-related vision impairment. Clinical trials for novel drug therapies are still ongoing till this day to enhance the efficacy of DR treatment. Even though there are also modern treatments such as laser therapy for the patients, prevention should be done to lower the number of individuals affected by DR. Due to the complexity of DR, there are numerous obstacles to develop new medications for DR which include the increasing healthcare cost of DR treatment. New insights such as utilisation of artificial intelligence will be implemented into the management of DR as it has proved its potential in aiding the screening process. In parallel with the increase in DR prevalence and the number of treatments developed, extensive understanding of the mechanism of action of DR should be further improved to prevent more complications in the future. This review summarises the epidemiological trend, prevention strategies, challenges in treatment, current novel therapeutics (including drugs under clinical trials), future therapeutic trends and possibilities for implementing AI in the early diagnosis and management of DR.

求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
Current diabetes reviews
Current diabetes reviews ENDOCRINOLOGY & METABOLISM-
CiteScore
6.30
自引率
0.00%
发文量
158
期刊介绍: Current Diabetes Reviews publishes frontier reviews on all the latest advances on diabetes and its related areas e.g. pharmacology, pathogenesis, complications, epidemiology, clinical care, and therapy. The journal"s aim is to publish the highest quality review articles dedicated to clinical research in the field. The journal is essential reading for all researchers and clinicians who are involved in the field of diabetes.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信